Postmortem brain studies have shown deficits in the cortical c-aminobutyric acid (GABA) system in schizophrenic individuals. Expression studies have shown a decrease in the major GABA-synthesizing enzyme (glutamic acid decarboxylase (GAD 67 ) mRNA levels in neurons in dorsolateral prefrontal cortex in schizophrenics relative to controls. In the present study, SNPs in and around the GAD1 gene, which encodes the protein GAD 67 , were tested on a rare, severely ill group of children and adolescents with childhood-onset schizophrenia (COS) (n ¼ 72), in a family-based association analysis. Compared to adult-onset samples, the COS sample has evidence for more salient familial, and perhaps genetic, risk factors for schizophrenia, as well as evidence for frontal cortical hypofunction, and greater decline in cortical gray matter volume on anatomic brain MRI scans during adolescence. We performed family-based TDT and haplotype association analyses of the clinical phenotype, as well as association analyses with endophenotypes using the QTDT program. Three adjacent SNPs in the 5 0 upstream region of GAD1 showed a positive pairwise association with illness in these families (P ¼ 0.022-0.057). Significant transmission distortion of 4-SNP haplotypes was also observed (P ¼ 0.003-0.008). Quantitative trait TDT analyses showed an intriguing association between several SNPs and increased rate of frontal gray matter loss. These observations, when taken together with the positive results reported recently in two independent adult-onset schizophrenia pedigree samples, suggest that the gene encoding GAD 67 may be a common risk factor for schizophrenia. Molecular Psychiatry (2005) 10, 581-588.
Schizophrenia is a severe psychiatric illness, thought to be at least in part a neurodevelopmental disorder resulting in abnormalities of synaptic connectivity. 1 The illness is associated with impaired function of the cerebral cortex, particularly the prefrontal, temporal, and cingulate regions. Reduction in the inhibitory role of GABAergic neurons has been hypothesized, and postmortem studies of brains of schizophrenic patients have found changes related to inhibitory g-aminobutyric acid A (GABA A ). Increased GABA A receptor binding has been reported in layers I and II of the cingulate cortex, and reduced GABA uptake and defective GABA release reported, implying that GABA transmission may be affected in schizophrenics. 2, 3 Glutamic acid decarboxylase (GAD) is the key enzyme in the synthesis of GABA in inhibitory interneurons. GAD exists as two isoforms (GAD 67 and GAD 65 ) with molecular masses of 67 and 65 kDa, which are encoded by different independently regulated genes on chromosomes 2 (GAD1) and 10 (GAD2), respectively. The two enzymes may have different physiological significance with regard to the synthesis, compartmentation, and release of GABA. 4 Both are present in most GABAcontaining neurons in the CNS, but GAD 65 appears to be targeted to membranes and nerve endings, whereas GAD 67 is more widely distributed in cells. 5 Studies of GAD 67 and GAD 65 knockout mice revealed very different phenotypes: GAD 65 À/À maintained normal levels of GABA, which was in sharp contrast to GAD 67 À/À mice that died the first morning after birth and GAD 67 þ /À mice that had about one-third reduction in GABA in cortex. 6, 7 A number of postmortem brain studies of schizophrenics have studied GAD expression. Akbarian et al 8 reported reduced prefrontal expression of GAD 67 in the absence of significant cell loss; axon terminals of chandelier neurons (which are GABAergic interneurons) were reduced in the middle layers of the prefrontal cortex (PFC); 9 GAD 67 mRNA expression was relatively unaltered in most PFC GABA neurons, but reduced below a detectable level in a subset of GABA neurons; 10 Guidotti et al 11 studied GAD 67 protein expression in the PFC as well as cerebellum, and found a 50% reduction in schizophrenic and bipolar patients as compared to controls. In contrast, there were no observed differences between psychiatric and nonpsychiatric subjects in the protein levels of GAD 65 . Taken together (though negative reports exist), these studies provide evidence supporting GAD1 as a candidate gene in the pathogenesis of schizophrenia, and for testing GAD2 in parallel for comparison.
Childhood-onset schizophrenia (COS), defined as the onset of psychotic symptoms by age 12, is a rare and severe form of the disorder. 12 Since 1990, patients with COS have been recruited nationally by the National Institute of Mental Health for clinical and neurobiological studies. COS appears clinically and neurobiologically continuous with the adult disorder 12 and a number of observations across pediatrics and medicine that early-onset cases may help identify a more homogeneous patient group that is less confounded by long-term effects of illness and may be caused by fewer genetic defects with higher penetrance. [13] [14] [15] Although COS is qualitatively continuous with adult-onset cases, the COS population appears quantitatively different in that there is a relatively higher rate of familial spectrum disorder, [16] [17] [18] and a higher rate of familial smooth pursuit eye movement abnormalities. 19 Further, COS is associated with poorer cognitive performance and more prominent early developmental abnormalities, 20 presumably reflecting more impaired early brain development than seen for later-onset patients. A positron emission tomography (PET) study using F-fluorodeoxyglucose (FDG) in a subset of these patients showed reduced frontal glucose metabolism similar to that seen in adult patients. 21 Finally, COS patients show a striking loss of gray matter volume as measured on serial MRI scanning through adolescence when compared with normal controls. The rate of reduction was related to premorbid impairment and baseline symptom severity, 22 and is also a greater rate of loss than reported for adult-onset cases. 23 In order to follow-up on the positive association observed between haplotypes in the GAD1 gene and two family samples of adult-onset schizophrenia, 24, 25 we tested SNPs at this locus for association in the childhood-onset sample. A second hypothesis was that SNPs in the GAD2 locus would not show association, consistent with expression studies. On a more exploratory level, we also tested for associations between genetic variation in GAD1 and quantitative measures of IQ, premorbid functioning, and rate of gray matter volume loss measured on MRI scans.
Subjects and methods
Patient recruitment and clinical assessment DNA was available for 72 children and adolescents who participated in the COS study. 12 In all, 66 had at least one parent available for study, the vast majority had both parents available (N ¼ 55). A total of 42 (58%) of the COS patients were males and, given the rarity of these patients (thus precluding selection), the ethnic background (based on parental report) was quite mixed: half the sample is Caucasian, 28% is African-American, and the remaining is a mix of Hispanic (7%), Asian (5.5%) and 10% from other or mixed ethnicities. The NIMH Institutional Review Board approved the project and written consent was obtained from parents and assent from minor subjects.
Patients meeting the DSM-III-R/DSM-IV 26 criteria for schizophrenia or psychosis NOS were recruited nationwide through an extensive screening process, including a review of over 1400 charts and in-person screening of over 230 subjects. The schizophrenic patients who participated were required to have a premorbid full-scale IQ of 70 or above and an onset of psychosis by the age of 12 (average age of onset of psychotic symptoms was 10 years.) The diagnosis of COS was confirmed by two psychiatrists (k ¼ 0.8) 27 through an extensive evaluation that included clinical and structured interviews of the children and parents using portions of the Schedule for Affective Disorders and Schizophrenia for School-Age Children (K-SADS-E and K-SADS-PL) 28, 29 and in-hospital observation during a 1-3-week medication-free period. Information on these subjects included cognitive and behavioral ratings of early development, history of medication response, neuropsychological test performance, smooth pursuit eye movements, and MRI scans.
Age of onset of first psychotic symptoms was obtained through interview and patient records. The mean age of patients when they entered our study was 14.4 years. Probands completed the Wechsler Intelligence Scale for Children-Revised (WISC-R) or Wechsler Intelligence Scale for Children-Third Edition (WISC-III). Premorbid development (defined as development up to 1 year before onset of psychosis) was evaluated based on clinical interview, neuropsychological testing, school records, standardized rating scales, and parental recall. As early-onset cases show more striking early developmental impairment, 12 ratings for early language, social, and educational adjustment were completed using a modification of the scale used by Hollis. 30 In addition, the Premorbid Adjustment Scale (PAS) 31 and the Autism Screening Questionnaire (ASQ), which has good discriminative validity with respect to the separation of Pervasive Developmental Disorder (PDD) from non-PDD diagnoses at all IQ levels, 32 were completed through parental interviews and chart review.
All patients underwent MRI scans on the same GE 1.5-T Sigma scanner during their initial in-patient stay at NIH and at 2-8-year follow-ups (details given elsewhere). 22 Volumes of the cerebrum and total and regional gray matter were obtained by using automated analysis, and percent change in volume across time was calculated. The rate of total and frontal gray matter volume change was calculated for the subjects with COS, who had at least two MRI scans available before age 21 (N ¼ 39). The total gray matter slope was defined as the follow-up scan value minus the first scan value divided by time elapsed between scans and expressed as milliliters per year (a negative value representing cortical volume reduction). This measure has been presented previously (see Sporn et al, 2003) . 22 Nucleic acid purification and PCR Genomic DNA was extracted from immortalized lymphoblastoid cells using the QIAamp DNA Extraction Kit (Qiagen, Inc., Valencia, CA, USA). SNPs in and around the GAD1 and GAD2 genes were selected from the Celera (http://www.celeradiscoverysystem. com/index.cfm) and dbSNP (http://www.ncbi.nlm. nih.gov/SNP/) databases, and are detailed in Table 1 . We used Primer Express Software (Applied Biosystems) to design TaqMan (fluorogenic 5 0 nuclease assay) primers and probes. Reactions were performed in a 384-well format in a total reaction volume of 10 ml with 2.0 ng of dried genomic DNA, 5 ml of 2 Â AmpliTaq Gold s PCR Master Mix (Applied Biosystems), 0.1 ml of each (1000 nM) primer, 0.02 ml of each (100 nM) probe, and 3.76 ml of 1 Â TE buffer. The plates were then placed in a thermal cycler (PE 9700; Applied Biosystems) and were heated at 501C for 2 min, then heated at 951C for 10 min, followed by 40 cycles of 951C for 30 s and 601C for 1 min. Then the plates were transferred to the Prism 7900HT (Applied Biosystems), in which the fluorescence intensity in each well of the plate was read.
Statistical analysis
We carried out error checking with the program MERLIN. 33 We measured linkage disequilibrium (LD) between markers with the D 0 and r 2 statistics from parental haplotypes by use of the program ldmax within the GOLD software package. 34 None of the SNPs deviated from Hardy-Weinberg equilibrium. Markers were tested for transmission disequilibrium, using the TDTPHASE program of the UNPHASED software package (http://www.hgmp.mrc.ac.uk/). Analyses were carried out through the Genetic Linkage User Environment (GLUE) interface. For the TDTPHASE analysis, we ran the analysis under the 'certain haplotypes' option, which implements the ETDT method for multiallelic markers and the algorithm developed by Dudbridge 35 to avoid the potential bias introduced by uncertain phase. We tested all two-, three-, and four-marker haplotypes for association in a sliding window across the locus. The option 'drop rare haplotypes' was used to restrict the analysis to the haplotypes with a frequency o3%. We carried out tests of association to quantitative traits using the program QTDT, which performed variancecomponents testing of family-based samples for association and transmission disequilibrium. 36 The orthogonal model used is robust to population stratification. In order to protect against possible inaccuracies due to deviations from either normality or selection on the trait, empirical P-values derived from 10 000 permutations are reported.
Results
We tested 14 SNPs in GAD1 and upstream of its start site. We concentrated on the 5 0 flanking region, under the assumption that, since GAD1 expression is decreased in schizophrenic brain, at least some of the regulatory elements influencing this dysregulation will be located there. The SNP locations and allele frequencies are shown in Table 1 . Also shown are the results from conventional (phase known) TDT analyses, which only counts allele transmissions from informative heterozygous parents. This analysis showed that the common allele of M06 was most strongly associated with schizophrenia, P ¼ 0.022. It is the SNPs in the 5 0 region of GAD1 that show a positive association with COS, whereas the remaining SNPs distal to intron 2 of the gene show no association. In contrast to these positive results in GAD1, none of the three GAD2 SNPs (rs2839670, rs3781109, rs3781106) tested showed a positive association in these families, P ¼ 0.37-0.79 (data not shown, details available upon request).
We computed marker-to-marker LD separately using the Caucasian and African-American subsamples. There was moderate LD between all markers throughout the GAD1 region in Caucasians, but this was not as clear in the African-American sample (see Table 2 ). This observation is consistent with the knowledge that LD between closely spaced markers tends to be less strong in African populations. 37 The haplotypes that encompass the 5 0 transcription start site and the protein initiator codon showed transmission distortion to schizophrenics. The detailed results of the only significantly associated four-marker haplotype, which contained markers M04-M07, is shown in Table 3 . We observed three common haplotypes accounting for 98% of the variation. The most common haplotype (65%)) was overtransmitted to affecteds (P ¼ 0.005).
A total of 30 quantitative intermediate phenotypes, including age of onset, 14 cognitive measures from the WISC (including IQ), 12 premorbid measures (described in the Subjects and methods section), eye tracking, and longitudinal gray matter loss, were tested for association with all 14 GAD1 SNPs. This QTDT analysis revealed that six out of 10 SNPs tested showed an association with more marked cortical gray matter loss over time, P ¼ 0.04-0.003. Four SNPs, M03, M05, M11, and M13, were not testable due to the small number of informative transmissions. In addition, M03 was associated with a poor qualitative eye-tracking score, P ¼ 0.003, thought to reflect 
Discussion
We observed a positive association between SNPs in the GAD1 locus, which encodes for the major GABAsynthesizing enzyme GAD 67 , and COS. The three SNPs that showed the strongest associations, M05, M06, and M07, are located in the 5 0 upstream region of the gene, from exon 1 (which is all 5 0 UTR), and in introns 1 and 2, respectively. This is perhaps not surprising, given the downregulation of the GAD 67 transcripts and protein observed in the PFC of schizophrenics. If these SNPs are tagging a diseaseassociated haplotype for schizophrenia, they may lead to a change in the expression level of GAD1 in 38, 39 though it remains to be seen if they are functional in the GAD1 promoter region. An alternative possibility is that these SNPs are in LD with other polymorphisms that affect transcription and/or splicing. In addition, these same SNPs and alleles showed a significant association with gray matter loss over time. Specifically, the common allele that was overtransmitted to affecteds was also associated with increased frontal gray matter volume loss on the MRI measures. This is a intriguing finding that deserves follow-up, particularly in light of the fact that we had multiple volumetric scans on only 39 of our cases for analysis. Moreover, other genes that we studied (eg G72, DTNBP1) 40, 41 did not show such an association, suggesting that this finding is not an artifact/confound under the diagnosis of COS. Finally, as we expected, there was no association observed between SNPs in the GAD2 locus, which encodes for GAD 65 .
Comparison of the findings in this study with the recent observations of association between GAD1 and two independently collected adult-onset samples is somewhat complicated by the fact that in the original work that we based our study on, they observed positive associations with different SNPs and haplotypes in each of their samples. 24, 25 In addition, in one of the two samples, they observed a significant association with distorted transmission only to female patients. Interestingly, when we subdivided our analysis by gender, the signal is similarly stronger in the females. Further, the haplotype that we observed to be significantly overtransmitted in the COS sample was characterized by the same common alleles as the significant haplotypes reported in the CBDB Sibling Study sample. 24, 25 One other paper by De Luca et al 42 recently reported a negative association with both the GAD1 and GAD2 genes, but those researchers tested only one SNP in each gene, which may have led to a false-negative result. In fact, the one SNP in GAD1 that they tested, rs769404, was also negative in the current study. Overall, the results of the endophenotype analyses indicated a relationship between variation in the GAD1 gene and an increased rate of frontal gray matter volume loss on MRI, and an association with eye-tracking deficits in a single but different SNP. While eye-tracking deficits may involve frontal lobe function, 43 other measures of prefrontal function (eg working memory subscales of the WISC, eg digit span) did not show association. While most of the SNPs tested revealed a positive association with increased frontal gray matter volume loss on MRI over time, one SNP, M03, also showed a positive association with eye-tracking dysfunction and a measure of premorbid functioning, which covers areas such as school, social, speech, and motor delays and difficulties. Given that the markers are in partial LD with each other and many of the phenotypic measures are also strongly correlated, the tests are not independent and therefore a Bonferroni correction would not be appropriate. We are not aware of a straightforward way to adjust for multiple testing in this situation, and recognize that type I errors are certainly cause for concern. We therefore present these endophenotype results as preliminary, but deserving of further study by other case-control and family samples. Nonetheless, we note that in our studies of three schizophrenia susceptibility genes to date, each gene demonstrates a very distinct pattern of association with the endophenotypic measures. Specifically, the G72 gene was associated with age of onset and scores on the Autism Screening Questionnaire, 40 while SNPs in the gene Dysbindin were associated with scores on the Premorbid Development Scale. 41 It is plausible that careful study of quantitative intermediate phenotypes in relationship to susceptibility genes for complex diseases such as schizophrenia can elucidate characteristic effects of each gene and how it may relate to the disease of interest.
As with most studies of rare diseases, many limitations exist. The children selected for this study were nationally recruited for an inpatient clinical trial and unknown referral bias is likely (eg more complete families, ability to travel, less ill parents). This group consisted of severely ill, treatment refractory subjects, and thus may not be representative of early-onset subjects in general. In addition, the small size of the sample greatly limits the power to detect associations, thus many of the SNPs that did not demonstrate association with either the clinical or endophenotypes may eventually do so in larger samples, and such efforts are now underway by at least two other research groups. Nonetheless, even given limited power, and the conservative TDT test utilized in this study, the fact that we did observe a strong association with SNPs in the GAD1 gene indicates that this gene may have a relatively large effect in this sample (relative risks ¼ 2.0-2.3). Studies of very early onset population with more pronounced neurobiological abnormalities and a more homogeneous phenotype may well turn out to be a relatively efficient population for the identification of some risk genes. Further strength for this argument is also provided by our recent report of an association with the G72 risk gene. 40 In conclusion, as might have been expected from numerous studies of dysfunctional regulation of molecules in the GABAergic system in the brains of schizophrenics, a family-based analysis showed that polymorphisms in the 5 0 upstream region of GAD1 were positively associated with COS and cortical gray matter loss over time. These observations, when taken together with the postmortem expression studies and the positive results obtained from two independent adult-onset schizophrenia pedigree samples, 24, 25 suggest that the gene encoding GAD 67 may prove to be a fairly common genetic risk factor for schizophrenia.
